...
首页> 外文期刊>Renal failure. >Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease
【24h】

Tonsillectomy delays progression of advanced IgA nephropathy to end-stage kidney disease

机译:扁桃体切除术延迟了晚期IgA肾病向终末期肾脏疾病的进展

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: Several investigators have described the effect of tonsillectomy on urinary abnormalities and long-term renal survival rates in patients with IgA nephropathy (IgAN), especially during the early stage of the disease. However, whether tonsillectomy affects the rate of IgAN progress, even when the disease is in the advanced stage, remains obscure. Methods: Of 365 patients who were histologically diagnosed with IgAN, 46 eventually reached end-stage kidney disease (ESKD) between 1981 and 2006. The periods from diagnosis to ESKD with renal replacement therapy (RRT) were compared between patients with ESKD who had undergone tonsillectomy (n = 15) as initial therapy for IgAN or not (n = 31). Relationships among risk factors, initial treatment, and rates of progression to ESKD were also examined using multivariate analysis in a retrospective cohort study of the 46 patients. Results: The duration between renal biopsy and initiation of RRT was significantly extended for patients with, than without, tonsillectomy (9.8 ± 6.0 vs. 5.8 ± 4.0 years, p = 0.007; unpaired t-test). The RRT-free survival advantage in patients with tonsillectomy was also evident in KaplanMeier curves (p = 0.007 by log-rank test). Logistic regression analysis showed that a high serum creatinine value at biopsy and severe histological damage were risk factors affecting rapid progression (within 7 years from diagnosis) to ESKD, whereas tonsillectomy apparently delayed disease progression [odds ratio, 0.09; 95% confidence interval (CI), 0.010.75; p = 0.026]. Conclusion: Tonsillectomy might delay the rate of progression even when IgAN is relatively advanced, although this study could not confirm whether it prevents progression to ESKD.
机译:目的:几位研究者描述了扁桃体摘除术对IgA肾病(IgAN)患者尿异常和长期肾脏存活率的影响,尤其是在疾病早期。但是,扁桃体切除术是否会影响IgAN的进展速度,即使该病处于晚期也仍然不清楚。方法:在1981年至2006年间,经组织学诊断为365例IgAN的患者中,有46例最终达到了终末期肾脏疾病(ESKD)。比较了接受肾脏替代疗法(RRT)从诊断到ESKD的时间,扁桃体切除术(n = 15)是否作为IgAN的初始治疗(n = 31)。在一项回顾性队列研究中对46例患者进行了多变量分析,分析了危险因素,初始治疗和发展为ESKD的比率之间的关系。结果:有或没有扁桃体切除术的患者,肾活检和开始RRT的时间明显延长(9.8±6.0 vs. 5.8±4.0年,p = 0.007;未配对t检验)。在KaplanMeier曲线中,扁桃体切除术患者的无RRT生存优势也很明显(对数秩检验p = 0.007)。 Logistic回归分析表明,活检时血清肌酐值高和严重的组织学损伤是影响ESKD快速进展(诊断后7年内)的危险因素,而扁桃体切除术显然延迟了疾病进展[几率,0.09; 95%置信区间(CI),0.010.75; p = 0.026]。结论:即使IgAN相对晚期,扁桃体切除术仍可能延迟进展速度,尽管该研究无法证实其是否能阻止进展为ESKD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号